Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)

Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R) is a phase 2, interventional study registered as NCT07183865 by Fudan University, with a registry enrolment figure of 44 participants, started 2025-03-09 and due to reach its primary completion in 2030-03-09. Interventions recorded: radiotherapy; Irinotecan Hydrochloride Liposome; 5-FU; Leucovorin; SG001; C225; Bevacizumab. Conditions listed: Locally Recurrent Rectal Cancer. Primary outcome: Local objective response rate. Sites: China. No results are recorded here; the registry entry is the source.